Mepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study

      Assess efficacy of 4-weekly add-on mepolizumab 100 mg SC on patient reported symptoms of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Co-primary endpoints of change from baseline in endoscopic NP score and nasal obstruction visual analogue scale (VAS) score have been previously reported.
      To read this article in full you will need to make a payment